David R. Spigel, MD
Dr. David R. Spigel is a medical oncologist who specializes in treating patients with lung cancer at the Sarah Cannon Research Institute in Nashville, Tennessee. As director of the lung cancer program there, he is actively involved in patient care and developing targeted therapies for the treatment of thoracic malignancies.[1]
Dr. Spigel is focused on providing his patients with a good quality of life as they fight cancer and describes his goal as helping his patients decide on the treatment options that best fit their circumstances, lifestyle, and wishes.[1]
Education and Career
Dr. Spigel earned his medical degree at the University of Tennessee College of Medicine. He then completed an internship and residency in Internal Medicine at Indiana University Medical Center and a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts.[1]
Dr. Spigel joined Sarah Cannon Cancer Research Institute in 2003 as the director of the lung cancer research program, and since then he has been involved in the development of immunotherapies and other targeted medicine in clinical trials there. In 2016 he was promoted to Chief Scientific Officer of the facility.[2]
Professional Memberships and Activities
Dr. Spigel is an active member of several esteemed professional medical societies, including being a board member of the Association of Community Cancer Centers membership in the American Society of Clinical Oncology, the American Association of Cancer Research, the International Association for the Study of Lung Cancer, and the Lung Cancer Research Foundation.[3]
Dr. Spigel has also served as an editor for several scientific publications, including Targeted Therapies,Oncology & Biotech News, Contemporary Oncology, and the World Journal of Clinical Oncology. He has also been a reviewer for many other publications.[3]
Research
In addition to his clinical practice, Dr. Spigel is the chief scientific officer at Sarah Cannon Research Institute. In this role, he oversees the facility’s clinical trial program, working directly with both physician leaders and pharma/biotech partners to bring the most innovative solutions to patients.
Dr. Spigel’s own research has been widely published in respected, peer-reviewed publications. He has had over 150 articles accepted by esteemed publications including The Lancet Oncology, The New England Journal of Medicine, the Journal of Medicine, the Journal of Thoracic Oncology, the Journal of Oncology Practice, and the Journal of Clinical Oncology. He has also been invited to present his research at scientific conferences around the world.[3]
Dr. Spigel’s research work includes:[4]
Clinical Trials
- Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer. Start of enrollment: 2004 Apr 01. COMPLETED. PHASE 1, PHASE 2
- Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer. Start of enrollment: 2005 Jul 01. COMPLETED. PHASE 2
- Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer. Start of enrollment: 2005 May 01. COMPLETED. PHASE 2
Publications
- A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Erica L Mayer, Nabihah Tayob, Siyang Ren, Jennifer J Savoie, David R Spigel, Howard A Burris 3rd, Paula D Ryan, Lyndsay N Harris, Eric P Winer, Harold J Burstein>; Breast Cancer Research and Treatment. 2024 Feb 1
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Tina Cascone, Gozde Kar, Jonathan D Spicer, Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin …> ;Cancer Discovery. 2023 Nov 1
- A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced S…Todd M Bauer, Kathleen N Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, J Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Anna V Tinker, Esteban Rodrigo Imedio,…>; Targeted Oncology. 2023 Jul 1
Journal Articles
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC . Roy S Herbst, Giuseppe Giaccone, David R Spigel, The New England Journal of Medicine
- Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1). Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
- Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC. David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
Lectures
- Reimbursement and Payment of Multiplex Testing in the United States. 2018 ASCO Annual Meeting – Chicago, Illinois – 06/3/2018
- Welcome and Introductions. 2018 ASCO Annual Meeting – Chicago, Illinois – 06/2/2018
Authored Content
- Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057. September 2018
